

Kyle Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6402596/publications.pdf>

Version: 2024-02-01

31
papers

1,228
citations

471509

17
h-index

434195

31
g-index

31
all docs

31
docs citations

31
times ranked

1690
citing authors

#	ARTICLE	IF	CITATIONS
1	Coronary Artery Calcifications and Cardiac Risk After Radiation Therapy for Stage III Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 188-196.	0.8	12
2	Hematologic Toxicity Comparison of Intensity Modulated Proton Therapy and Intensity Modulated Radiation Therapy in Anal Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 264-267.	1.3	2
3	Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 227-236.	0.8	23
4	Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 68-75.	1.3	4
5	The impact of pathologic staging of the hilar/mediastinal nodes on outcomes in patients with early-stage NSCLC receiving stereotactic body radiotherapy. <i>Journal of Thoracic Disease</i> , 2021, 13, 1045-1054.	1.4	4
6	NTCP modeling and dose-volume correlations for acute xerostomia and dry eye after whole brain radiation. <i>Radiation Oncology</i> , 2021, 16, 56.	2.7	3
7	Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 237-248.	0.8	40
8	Radiation therapy-associated toxicity: Etiology, management, and prevention. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 437-454.	329.8	129
9	Does Timing Matter? Surgical Outcomes in High-Grade Sarcomas after Neoadjuvant Radiation Therapy. <i>Journal of Surgical Research</i> , 2020, 254, 118-124.	1.6	2
10	Prospective Assessment of Patient-Reported Dry Eye Syndrome After Whole Brain Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 765-772.	0.8	15
11	A Prospective Analysis of Radiation Oncologist Compliance With Early Peer Review Recommendations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 494-500.	0.8	15
12	Smoking Cessation and Low-Dose Computed Tomography Screening: A Necessary Pair. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1495-1497.	1.1	2
13	Shoulder symptoms and quality of life impact of limited neck dissection after de-intensified chemoradiotherapy: Secondary analysis of two prospective trials. <i>Head and Neck</i> , 2019, 41, 1213-1219.	2.0	6
14	Assessment of Risk of Xerostomia After Whole-Brain Radiation Therapy and Association With Parotid Dose. <i>JAMA Oncology</i> , 2019, 5, 221.	7.1	19
15	Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 646-653.	0.8	27
16	Pitfalls of post-treatment PET after de-intensified chemoradiotherapy for HPV-associated oropharynx cancer: Secondary analysis of a phase 2 trial. <i>Oral Oncology</i> , 2018, 78, 108-113.	1.5	19
17	Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture. <i>Clinical Cancer Research</i> , 2018, 24, 2539-2547.	7.0	32
18	Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1508-1518.	1.1	63

#	ARTICLE	IF	CITATIONS
19	Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1387-1394.	1.6	318
20	The Role of Radiation Therapy in the Management of Sinonasal and Ventral Skull Base Malignancies. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 419-432.	1.1	17
21	Truth or myth: Definitive chemoradiotherapy doesn't work for HPV/p16 negative oropharyngeal squamous cell carcinoma?. <i>Oral Oncology</i> , 2017, 65, 125-126.	1.5	1
22	Influence of Fractionation Scheme and Tumor Location on Toxicities After Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-institutional Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 778-785.	0.8	50
23	Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 293-300.	0.6	91
24	Incidence of, and risk factors for, mandibular osteoradionecrosis in patients with oral cavity and oropharynx cancers. <i>Oral Oncology</i> , 2017, 72, 98-103.	1.5	119
25	Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumors. <i>Cancer</i> , 2017, 123, 688-696.	4.1	86
26	Evaluation of PET/MRI for Tumor Volume Delineation for Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 8.	2.8	22
27	Impact of post-chemoradiotherapy superselective/selective neck dissection on patient reported quality of life. <i>Oral Oncology</i> , 2016, 58, 21-26.	1.5	10
28	Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database. <i>Cancer</i> , 2016, 122, 3069-3074.	4.1	8
29	Target delineation in stereotactic body radiation therapy for recurrent head and neck cancer: A retrospective analysis of the impact of margins and automated PET-CT segmentation. <i>Radiotherapy and Oncology</i> , 2013, 106, 90-95.	0.6	39
30	<i>Caenorhabditis elegans</i> POT-1 and POT-2 Repress Telomere Maintenance Pathways. <i>G3: Genes, Genomes, Genetics</i> , 2013, 3, 305-313.	1.8	29
31	A retrospective, deformable registration analysis of the impact of PET-CT planning on patterns of failure in stereotactic body radiation therapy for recurrent head and neck cancer. <i>Head & Neck Oncology</i> , 2012, 4, 12.	2.3	21